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The highly complex structure of the human brain is strongly shaped
by genetic influences1. Subcortical brain regions form circuits with
cortical areas to coordinate movement2, learning, memory3 and
motivation4, and altered circuits can lead to abnormal behaviour
anddisease2. To investigate how commongenetic variants affect the
structure of thesebrain regions, herewe conduct genome-wide asso-
ciation studies of the volumes of seven subcortical regions and the
intracranial volume derived from magnetic resonance images of
30,717 individuals from 50 cohorts. We identify five novel genetic
variants influencing thevolumesof theputamenandcaudatenucleus.
We also find stronger evidence for three loci with previously estab-
lished influences onhippocampal volume5 and intracranial volume6.
These variants show specific volumetric effects on brain structures
rather thanglobal effects across structures. The strongest effectswere
found for theputamen,where anovel intergenic locuswith replicable
influence on volume (rs945270; P5 1.083 10233; 0.52% variance
explained) showed evidence of altering the expression of the KTN1
gene in both brain and blood tissue. Variants influencing putamen
volume clusterednear developmental genes that regulate apoptosis,
axon guidance and vesicle transport. Identification of these genetic
variantsprovides insight into thecauses of variability inhumanbrain
development, andmay help to determinemechanisms of neuropsy-
chiatric dysfunction.
At the individual level, genetic variations exert lasting influences on
brain structures and functions associatedwithbehaviour andpredispo-
sition to disease. Within the context of the Enhancing Neuro Imaging
Genetics throughMeta-Analysis (ENIGMA)consortium,weconducted
a collaborative large-scale genetic analysis ofmagnetic resonance imag-
ing (MRI) scans to identify genetic variants that influencebrain structure.
Here,we focus on volumetricmeasures derived fromameasure of head
size (intracranial volume, ICV) and seven subcortical brain structures
corrected for the ICV(nucleus accumbens, caudate, putamen, pallidum,
amygdala, hippocampus and thalamus). To ensure data homogeneity
within the ENIGMA consortium, we designed and implemented stan-
dardizedprotocols for image analysis, quality assessment, genetic impu-
tation (to1000Genomes references, version3) andassociation (Extended
Data Fig. 1 and Methods).
After establishing that the volumes extracted using our protocols
were substantially heritable in a large sample of twins (P, 13 1024;
seeMethods and Extended Data Fig. 11a), with similar distributions to
previous studies1, we sought to identify common genetic variants con-
tributing to volume differences by meta-analysing site-level genome-
wide association study (GWAS) data in a discovery sample of 13,171
subjects of European ancestry (ExtendedData Fig. 2). Population strat-
ificationwas controlled for by including, as covariates, four population
components derived from standardizedmultidimensional scaling ana-
lysesof genome-widegenotypedata conducted at each site (seeMethods).
Site-level GWAS results and distributions were visually inspected to
check for statistical inflation and patterns indicating technical artefacts
(see Methods).
Meta-analysis of thediscovery sample identified six genome-wide sig-
nificant loci after correcting for the number of variants and traits ana-
lysed (P, 7.13 1029; seeMethods): one associated with the ICV, two
associatedwith hippocampal volume, and threewith putamen volume.
Another four loci showed suggestive associations (P, 13 1027) with
putamen volume (one locus), amygdala volume (two loci), and caudate
volume (one locus;Table 1, Fig. 1 andSupplementaryTable 5).Quantile–
quantile plots showed no evidence of population stratification or cryp-
tic relatedness (ExtendedData Fig. 4a).We subsequently attempted to
replicate the variants with independent data from 17,546 individuals.
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Figure 1 | Common genetic variants associated with subcortical volumes
and the ICV. Manhattan plots coloured with a scheme that matches the
corresponding structure (middle) are shown for each subcortical volume
studied. Genome-wide significance is shown for the common threshold of
P5 53 1028 (grey dotted line) and also for the multiple comparisons-
corrected threshold of P5 7.13 1029 (red dotted line). The most significant
SNP within an associated locus is labelled.
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All subcortical genome-wide significant variants identified in the dis-
covery sample were replicated (Table 1). The variant associated with
the ICV did not replicate in a smaller independent sample, but was
genome-wide significant in a previously published independent study6,
providing strong evidence for its association with the ICV. Moreover,
two suggestive variants associated with putamen and caudate volumes
exceeded genome-wide significance after meta-analysis across the dis-
covery and replicationdata sets (Table1). Effect sizeswere similar across
cohorts (P. 0.1, Cochran’sQ test; ExtendedData Fig. 4b). Effect sizes
remained consistent after excluding patients diagnosed with anxiety,
Alzheimer’s disease, attention-deficit/hyperactivity disorder, bipolar
disorder, epilepsy,major depressive disorder or schizophrenia (21%of
the discovery participants). Correlation in effect size with and without
patientswas very high (r. 0.99) for loci withP, 13 1025, indicating
that these effects were unlikely to be driven by disease (Extended Data
Fig. 5a). The participants’ age range covered most of the lifespan (9–
97 years), but onlyoneof the eight significant loci showedaneffect related
to the mean age of each cohort (P5 0.002; rs6087771 affecting puta-
men volume; Extended Data Fig. 5b), suggesting that nearly all effects
are stable across the lifespan. In addition, none of these loci showed
evidence of sex effects (Extended Data Fig. 5c).
In our cohorts, significant loci were associated with 0.51–1.40% dif-
ferences in volume per risk allele, explaining 0.17–0.52% of the pheno-
typic variance (Table 1); such effect sizes are similar to those of common
variants influencing other complex quantitative traits such as height7
andbodymass index8.The full genome-wideassociation results explained
7–15% of phenotypic variance after controlling for the effects of cov-
ariates (Extended Data Fig. 11). Notably, the genome-wide significant
variants identified here showed specific effects on single brain struc-
tures rather than pleiotropic effects across multiple structures, despite
similar developmental origins as in the case of caudate and putamen
(Extended Data Fig. 6a). Nevertheless, when we subjected the subcor-
ticalmeta-analysis results tohierarchical clustering, genetic determinants
of the subcortical structures were mostly grouped into larger circuits
according to their developmental and functional subdivisions (Extended
Data Fig. 6b). Genetic variants may therefore have coherent effects on
functionally associatedsubcorticalnetworks.Multivariate cross-structure9
analyses confirmed the univariate results, butnoadditional loci reached
genome-wide significance (Extended Data Fig. 6c). The clustering of
results into known brain circuits in the absence of individually signi-
ficant genetic variants found in the cross-structure analysis suggests
variants of small effect may have similar influences across structures.
Most variants previously reported to be associatedwith brain structure
and/or function showed little evidence of large-scale volumetric effects
(Supplementary Table 8). We detected an intriguing association with
hippocampal volume at a single nucleotide polymorphism (SNP)with
a genome-wide significant associationwith schizophrenia10 (rs2909457;
P5 2.123 1026; where theA allele is associatedwith decreased risk for
schizophrenia and decreased hippocampal volume). In general, how-
ever, we detected no genome-wide significant association with brain
structure for genome-wide significant loci that contribute risk for neu-
ropsychiatric illnesses (Supplementary Table 9).
Of the four loci influencing putamen volume, we identified an inter-
genic locus 50 kilobases (kb) downstream of theKTN1 gene (rs945270;
14q22.3;n5 28,275;P5 1.08310233),which encodes theproteinkinec-
tin, a receptor that allows vesicle binding to kinesin and is involved in
organelle transport11. Second,we identified an intronic locuswithinDCC
(rs62097986; 18q21.2; n5 28,036;P5 1.013 10213), which encodes a
netrin receptor involved in axon guidance and migration, including in
the developing striatum12 (Extended Data Fig. 3b). Expression ofDCC
throughout the brain is highest in the first two trimesters of prenatal
development13 (ExtendedData Fig. 8b), suggesting that this variantmay
influence brain volumes early in neurodevelopment. Third, we iden-
tified an intronic locuswithinBCL2L1 (rs6087771; 20q11.21;n5 25,540;
P5 1.283 10212),which encodes an anti-apoptotic factor that inhibits
programmed cell death of immature neurons throughout the brain14
(Extended Data Fig. 3c). Consistent with this, expression of BCL2L1 in
the striatum strongly decreases at the end of neurogenesis (24–38 post-
conception weeks (PCW); Extended Data Fig. 8c), a period marked by
increased apoptosis in theputamen13,15. Fourth,we identified an intronic
locus withinDLG2 (rs683250; 11q14.1; n5 26,258;P5 3.943 10211),
which encodes the postsynaptic density93 (PSD-93) protein (Extended
DataFig. 3d).PSD-93 is amembrane-associatedguanylatekinase involved
in organizing channels in the postsynaptic density16.DLG2 expression
increases during earlymid-fetal development in the striatum13 (Extended
Data Fig. 8d). Genetic variants in DLG2 affect learning and cognitive
flexibility17 andare associatedwith schizophrenia18.Notably, SNPs asso-
ciated with variation in putamen volume showed enrichment of genes
involved in apoptosis and axon guidance pathways (Extended Data
Fig. 7 and Supplementary Table 7).
Hippocampal volumeshowedan intergenic associationnear theHRK
gene (rs77956314; 12q24.22; n5 17,190; P5 2.823 10215; Extended
DataFig. 3g) andwith an intronic locus in theMSRB3gene (rs61921502;
12q14.3;n5 16,209;P5 6.873 10211; ExtendedData Fig. 3h), support-
ing our previous analyses5,19 of smaller samples imputed to HapMap3
references.Caudate volumewas associatedwith an intergenic locus 80 kb
fromFAT3 (rs1318862; 11q14.3;n5 15,031;P5 6.173 1029; Extended
Data Fig. 3e). This gene encodes a cadherin specifically expressed in the
Table 1 | Genetic variants at eight loci were significantly associated with putamen, hippocampus, caudate nucleus and ICV
Discovery cohort Replication cohort Discovery 1 replication cohorts
Trait Marker A1 A2 Frq Effect (se) P value Sample
size
Effect (se) P value Sample
size
Effect (se) P value Total
sample
size
Variance
explained
(%)
Diff./
allele
(%)
Putamen rs945270 C G 0.58 60.64
(6.00)
5.43310224 13,145 39.15
(5.46)
7.81310213 15,130 48.89
(4.04)
1.08310233 28,275 0.52 0.94
Putamen rs62097986 A C 0.44 39.53
(6.01)
4.86310211 13,145 22.46
(5.53)
4.8931025 14,891 30.28
(4.07)
1.01310213 28,036 0.20 0.58
Putamen rs6087771 T C 0.71 40.72
(6.82)
2.4231029 11,865 26.97
(6.57)
4.0231025 13,675 33.58
(4.73)
1.28310212 25,540 0.20 0.64
Putamen rs683250 A G 0.63 233.97
(6.08)
2.3331028 13,145 222.30
(5.89)
1.5031024 13,113 227.95
(4.23)
3.94310211 26,258 0.17 0.51
Caudate rs1318862 T C 0.58 26.27
(4.89)
7.5431028 13,171 31.82
(14.23)
0.025 1,860 26.86
(4.62)
6.1731029 15,031 0.22 0.74
Hip. rs77956314 T C 0.91 254.21
(8.37)
9.33310211 13,163 257.43
(12.69)
6.0431026 4,027 255.18
(6.99)
2.82310215 17,190 0.36 1.40
Hip. rs61921502 T G 0.84 43.40
(6.89)
2.92310210 13,163 26.81
(13.32)
0.044 3,046 39.90
(6.12)
6.87310211 16,209 0.26 1.01
ICV rs17689882 A G 0.22 215,335.88
(2,582.20)
2.8731029 10,944 25,202.15
(5,428.60)
0.337 1,878 213,460.47
(2,331.05)
7.7231029 12,822 0.26 0.96
The allele frequency (frq) and effect size are given with reference to allele 1 (A1). Effect sizes are given in units of mm3 per effect allele. Results are provided for the discovery samples and the combined meta-
analysis of the discovery and replication cohorts (all European ancestry). Additional validation was attempted in non-European ancestry generalization samples (shown in Supplementary Table 6). The variance
explained gives the percentage variance explained by a given SNP after correcting for covariates (see Methods for additional details). The percentage difference in volume per effect allele (Diff./allele) is based on
the absolute value of the final combined effect divided by a weighted average of the brain volume of interest across all sites in the discovery sample and then multiplied by 100. Hip, hippocampus.
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nervous system during embryonic development that influences neu-
ronal morphology through cell–cell interactions20. The ICV was asso-
ciated with an intronic locus withinCRHR1 that tags the chromosome
17q21 inversion21, which has been previously found to influence ICV6
(rs17689882; 17q21.31; n5 12,822; P5 7.723 1029; Extended Data
Fig. 3f). Another previously identified variant with association to ICV
(rs10784502)5,19 didnot survive genome-wide significance in this analysis
but did show a nominal effect in the same direction (P5 2.053 1023;
n5 11,373). None of the genome-wide significant loci in this study
were in linkage disequilibriumwith known functional coding variants,
splice sites, or 39/59 untranslated regions, although several of the loci
had epigenetic markings suggesting a regulatory role (Extended Data
Fig. 3).
Given the strongassociationwithputamenvolume,we further exam-
ined the rs945270 locus. Epigeneticmarkers suggest insulator function-
ality near the locus as this is the lone chromatin mark in the intergenic
region22 (ExtendedData Fig. 3a). Chromatin immunoprecipitation fol-
lowed by sequencing (ChIP-seq) indicate that a variant (rs8017172)
in complete linkage disequilibriumwith rs945270 (r2 5 1.0) lies within
a binding site of the CTCF (CCCTC-binding factor) transcription
regulator23 (Extended Data Fig. 9) in embryonic stem cells. To assess
potential functionality in brain tissue,we tested for associationwith gene
expression 1megabase (Mb) up/downstream. We identified and rep-
licated an effect of rs945270 on the expression of the KTN1 gene. The
C allele, associatedwith larger putamen volume, also increased expres-
sion ofKTN1 in the frontal cortex (discovery sample: 304 neuropatho-
logically normal controls24 (P5 4.13 10211); replication sample: 134
neuropathologicallynormal controls (P5 0.025)), andputamen (sample:
134 neuropathologically normal controls25 (P5 0.049); Fig. 2a, b). In
blood, rs945270 was also strongly associated with KTN1 expression26
(P5 5.943 10231; n5 5,311). After late fetal development, KTN1 is
expressed in thehuman thalamus, striatumandhippocampus; it ismore
highly expressed in the striatumthan the cortex13 (ExtendedDataFig. 8a).
KTN1 encodes the kinectin receptor facilitating vesicle binding tokinesin,
and is heavily involved in organelle transport11. Kinectin is only found
in the dendrites and soma of neurons, not their axons; neurons with
more kinectinhave larger cell bodies27, andkinectin knockdownstrongly
influences cell shape28. The volumetric effects identifiedheremay there-
fore reflect genetic control ofneuronal cell size and/ordendritic complex-
ity.Using three-dimensional surfacemodels of putamen segmentations
inMRI scans of 1,541 healthy adolescent subjects, we further localized
the allelic effects of rs945270 to regions along the superior and lateral
putamen bilaterally, independent of chosen segmentation protocol
(Fig. 2c and ExtendedData Fig. 10). Each copy of the C allele was asso-
ciatedwith an increase in volumealong anterior superior regions receiv-
ing dense cortical projections from dorsolateral prefrontal cortex and
supplementary motor areas29,30.
In summary,wediscovered several commongenetic variants underly-
ing variation indifferent structureswithin thehumanbrain.Many seem
to exert their effects through known developmental pathways includ-
ing apoptosis, axonguidance andvesicle transport.All structure volumes
showed high heritability, but individual genetic variants had diverse
effects. The strongest effectswere found for putamen and hippocampal
volumes,whereas other structuresdelineatedwith similar reliability such
as the thalamus showed no association with these or other loci (Sup-
plementaryTable 4).Discoveryof commonvariants affecting thehuman
brain is now feasible using collaborative analysis ofMRI data, andmay
determine genetic mechanisms driving development and disease.
Online ContentMethods, along with any additional Extended Data display items
andSourceData, are available in theonline versionof thepaper; referencesunique
to these sections appear only in the online paper.
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METHODS
Details of the GWASmeta-analysis are outlined in ExtendedData Fig. 1. All parti-
cipants in all cohorts in this study gavewritten informed consent and sites involved
obtained approval from local research ethics committees or Institutional Review
Boards. The ENIGMA consortium follows a rolling meta-analysis framework for
incorporating sites into the analysis. The discovery sample comprises studies of
European ancestry (Extended Data Fig. 2) that contributed GWAS summary sta-
tistics for the purpose of this analysis on or before 1October 2013. The deadline for
discovery samples to upload their data was made before inspecting the data and
was not influenced by the results of the analyses. The meta-analysed results from
discovery cohorts were carried forward for secondary analyses and functional vali-
dation studies. Additional samples of European ancestry were gathered to provide
in silico or single genotype replication of the strongest associations as part of the
replication sample. A generalization sample of sites with non-European ancestry
was used to examine the effects across ethnicities. In all, data were contributed
from 50 cohorts, each of which is detailed in Supplementary Tables 1–3.
The brain measures examined in this study were obtained from structural MRI
data collected at participating sites around the world. Brain scans were processed
and examined at each site locally, following a standardized protocol procedure to
harmonize the analysis across sites. The standardized protocols for image analysis
andquality assurance areopenly available online (http://enigma.ini.usc.edu/protocols/
imaging-protocols/). The subcortical brain measures (nucleus accumbens, amyg-
dala, caudate nucleus, hippocampus, pallidum,putamenand thalamus)weredelin-
eated in the brain usingwell-validated, freely available brain segmentation software
packages: FIRST31, part of the FMRIB Software Library (FSL), or FreeSurfer32. The
agreement between the two software packages has been well documented in the
literature5,33 and was further detailed here (Supplementary Table 4). Participating
sites used the software packagemost suitable for their data set (the software used at
each site is given in Supplementary Table 2) without selection based on genotype
or the associations present in this study. In addition to the subcortical structures of
the brain,we examined the genetic effects of ameasure of global head size, the ICV.
The ICVwas calculatedas: 1/(determinant of a rotation-translationmatrixobtained
after affine registration to a common study template and multiplied by the tem-
plate volume (1,948,105mm3)). After image processing, each imagewas inspected
individually to identify poorly segmented structures. Each site contributed histo-
grams of the distribution of volumes for the left and right hemisphere structures
(and ameasure of asymmetry) of each subcortical regionused in the analysis. Scans
marked as outliers (.3 standarddeviations fromthemean)basedon thehistogram
plots were re-checked at each site to locate any errors. If a scan had an outlier for a
given structure, but was segmented properly, it was retained in the analysis. Site-
specific phenotype histograms, Manhattan plots and quantile–quantile plots from
eachparticipating site are available on the ENIGMAwebsite (http://enigma.ini.usc.
edu/publications/enigma-2/).
Each study in the discovery samplewas genotyped using commercially available
platforms. Before imputation, genetic homogeneity was assessed in each sample
usingmulti-dimensional scaling (MDS) analysis (Extended Data Fig. 2). Ancestry
outlierswere excluded throughvisual inspectionof the first two components.Quality
control filtering was applied to remove genotyped SNPs with low minor allele
frequency (,0.01), poor genotype call rate (,95%), and deviations fromHardy–
Weinberg equilibrium (P, 13 1026) before imputation. The imputation proto-
cols used MaCH34 for haplotype phasing and minimac35 for imputation and are
freely available online (http://enigma.ini.usc.edu/protocols/genetics-protocols/).
Full details of quality control procedures and any deviations from the imputation
protocol are given in Supplementary Table 3.
Genome-wide association scans were conducted at each site for all eight traits of
interest including the ICV and bilateral volumes of the nucleus accumbens, amyg-
dala, caudatenucleus, hippocampus, pallidum,putamenand thalamus. For eachSNP
in the genome, the additive dosage value was regressed against the trait of interest
separately using a multiple linear regression framework controlling for age, age2,
sex, 4MDScomponents, ICV(fornon-ICVphenotypes) anddiagnosis (whenappli-
cable). For studieswithdata collected fromseveral centresor scanners, dummy-coded
covariates were also included in the model. Sites with family data (NTR-Adults,
BrainSCALE, QTIM, SYS, GOBS, ASPSFam, ERF, GeneSTAR,NeuroIMAGE and
OATS) used mixed-effects models to control for familial relationships in addition
to covariates stated previously. The primary analyses for this paper focused on the
full set of subjects including data sets with patients tomaximize the power to detect
effects. We re-analysed the data excluding patients to verify that detected effects
were not due to disease alone (ExtendedData Fig. 5a). The protocols used for test-
ing associationwithmach2qtl (ref. 34) for studieswithunrelated subjects andmerlin-
offline36 for family-based designs are freely available online (http://enigma.ini.usc.
edu/protocols/genetics-protocols/). Full details for the software used at each site
are given in Supplementary Table 3.
TheGWAS results from each sitewere uploaded to a centralized server for quality
checking and processing. Results files from each cohort were free from genomic
inflation in quantile–quantile plots and Manhattan plots (http://enigma.ini.usc.
edu/publications/enigma-2/). Poorly imputed SNPs (withR2,0.5) and lowminor
allele count (,10) were removed from the GWAS result files from each site. The
resulting fileswere combinedmeta-analyticallyusing a fixed-effect, inverse-variance-
weightedmodel as implemented in the software packageMETAL37. The discovery
cohorts weremeta-analysed first, controlling for genomic inflation. The combined
discovery data set (comprised of all meta-analysed SNPs with data from at least
5,000 subjects) was carried forward for the additional analyses detailed below.
To account appropriately for multiple comparisons over the eight traits in our
analysis,we first examined the degree of independence between each trait.Wegen-
erated an 8 3 8 correlation matrix based on the Pearson’s correlation between all
pair-wise combinations of themean volumes of each structure in the QTIM study.
Using the matSpD software38 we found that the effective number of independent
traits in our analysis was 7. We therefore set a significance criteria threshold of
P, (53 1028/7)5 7.13 1029.
Heritability estimates for mean volumes of each of the eight structures in this
studywere calculatedusing structural equationmodelling inOpenMx39. Twinmod-
elling was performed controlling for age and sex differences on a large sample
(n5 1,030) of healthy adolescent and young adult twins (148 monozygotic and
202dizygotic pairs) and their siblings from theQueenslandTwin Imaging (QTIM)
study. Subsequently, a multivariate analysis showed that common environmental
factors (C) could be dropped from themodel without a significant reduction in the
goodness-of-fit (Dx2365 29.81; P5 0.76). Heritability (h
2) was significantly dif-
ferent from zero for all eight brain measures: putamen (h2 5 0.89; 95% confidence
interval 0.85–0.92), thalamus (h2 5 0.88; 0.85–0.92), ICV (h2 5 0.88; 0.84–0.90),
hippocampus (h2 5 0.79; 0.74–0.83), caudate nucleus (h2 5 0.78; 0.75–0.82), pal-
lidum (h2 5 0.75; 0.72–0.78), nucleus accumbens (h2 5 0.49; 0.45–0.55), amygdala
(h2 5 0.43; 0.39, 0.48) (Extended Data Fig. 11a).
Percentage variance explained by each genome-wide significant SNPwas deter-
mined based on the final combined discovery data set (Extended Data Fig. 6a) or
the discovery combined with the replication samples (Table 1) after correction for
covariates using the following equation:
R2gjc=(1{R
2
c )~(t
2=((n{k{1)zt2))  100
where the t-statistic is calculated as the beta coefficient for a given SNP from the
regression model (controlling for covariates) divided by the standard error of the
beta estimate, andwhere n is the total number of subjects and k is the total number
of covariates included in themodel (k5 10) (ref. 40).R2gjc is the variance explained
by the variant controlling for covariates and R2c is the variance explained by the
covariates alone.R2gjc/(12R
2
c) gives the variance explained by the genetic variant
after accounting for covariate effects. The total variance explained by the GWAS
(Extended Data Fig. 11b, c) was calculated by first linkage disequilibrium pruning
the results without regard to significance (pruning parameters in PLINK:––indep-
pairwise 1000kb 25 0.1). The t-statistics of the regression coefficients from the
pruned results are then corrected for the effects of ‘winner’s curse’ and the variance
explained by eachSNPafter accounting for covariate effects is summedacross SNPs
using freely available code (http://sites.google.com/site/honcheongso/software/
total-vg)40,41. As the correction for winners curse may be influenced by asymmetry
in the distribution of t (arising from the choice of reference allele) we bootstrapped
the choice of reference allele (5,000 iterations) to derive the median value and 95%
confidence intervalsof the estimatesof varianceexplained (ExtendedDataFig. 11b, c).
The correction forwinner’s curse corrected for upward biaseswhen estimating the
percentage variance explained by each SNP across the genome via simulation40,
but this correction could still allow some bias. Future large studies will be able to
evaluate independently the percentage variance explained.
We performed multivariate GWAS using the Trait-based Association Test that
uses ExtendedSimes procedure (TATES)9. For theTATESanalysisweusedGWAS
summary statistics from the discovery data set and the correlation matrix created
from the eight phenotypes using the QTIM data set (Extended Data Fig. 6c).
We examined themoderating effects of mean age and proportion of females on
the effect sizes estimated for the top loci influencing brain volumes (ExtendedData
Fig. 5b, c) using a mixed-effect meta-regression model such that:
effect~b0zbmodXmodzezg
In this model, the effect and variance at each site are treated as random effects and
themoderatorXmod (eithermean age or proportion of females) is treated as a fixed
effect. Meta-regression tests were performed using the metafor package (version
1.9-1) in R.
Hierarchical clustering was performed on the GWAS t-statistics from the dis-
covery data set results using independent SNPs clumped from the TATES results
(clumping parameters: significance threshold for index SNP5 0.01, significance
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threshold for clumpedSNPs5 0.01, r2 5 0.25, physical distance5 1Mb;Extended
Data Fig. 6b). Regions with the strongest genetic similarity were grouped together
based on the strength of their pairwise correlations. The results were represented
visually using hierarchical clustering with default settings from the gplots package
(version 2.12.1) in R.
Gene annotation, gene-based test statistics andpathway analysiswereperformed
using the KGG2.5 software package42 (Supplementary Table 7 and Extended Data
Fig. 7). Linkage disequilibrium was calculated based on RSID numbers using the
1000GenomesProject European samples as a reference (http://enigma.ini.usc.edu/
protocols/genetics-protocols/). For the annotation, SNPs were considered ‘within’
a gene if they fell within 5 kb of the 39/59 untranslated regions based on human
genome (hg19) coordinates. Gene-based tests were performed using the GATES
test42 without weighting P values by predicted functional relevance. Pathway ana-
lysis was performed using the hybrid set-based test (HYST) of association43. For all
gene-based tests and pathway analyses, results were considered significant if they
exceeded a Bonferroni correction threshold accounting for the number of path-
ways and traits tested such that Pthresh5 0.05/(671 pathways3 7 independent
traits)5 1.063 1025.
Expression quantitative loci were examined in two independent data sets: the
NABEC (GSE36192)24 andUKBEC(GSE46706)44,45.Detailedprocessing and exclu-
sion criteria for both data sets are described elsewhere24,45. In brief, the UKBEC
consists of 134 neuropathologically normal donors from the MRC Sudden Death
Brain Bank in Edinburgh and Sun Health Research Institute; expression was pro-
filed on the Affymetrix Exon 1.0 ST array. The NABEC is comprised of 304 neu-
rologically normal donors from the National Institute of Ageing and expression
profiled on the Illumina HT12v3 array. The expression values were corrected for
gender and batch effects and probes that contained polymorphisms (seen .1%
in European 1000G) were excluded from analyses44. Blood expression quantita-
tive trait loci (eQTL) data were queried using the Blood eQTL Browser (http://
genenetwork.nl/bloodeqtlbrowser/)26. Brain expression over the lifespanwasmea-
sured from a spatio-temporal atlas of human gene expression and graphed using
custom R scripts (GSE25219; details given in13).
Fine-grained three-dimensional surfacemappings of theputamenwere generated
using a medial surface modelling method46,47 in 1,541 healthy subjects from the
IMAGEN study48 (Fig. 2c and Extended Data Fig. 10a, b). Putamen volume seg-
mentations from either FSL (Fig. 2c and Extended Data Fig. 10a) or FreeSurfer
(Extended Data Fig. 10b) were first converted to three-dimensional meshes and
then co-registered to an average template for statistical analysis. The medial core
distance was used as a measure of shape and was calculated as the distance from
eachpoint on the surface to the centre of the putamen.At eachpoint along the sur-
face of the putamen, an association testwasperformedusingmultiple linear regres-
sion in which the medial core distance at a given point on the surface was the
outcomemeasure and the additive dosage value of the top SNPwas the predictor of
interest while including the same covariates that were used for volume including
age, sex, age2, 4 MDS, ICV and site.
In Extended Data Fig. 3, all tracks were taken from the UCSCGenome Browser
Human hg19 assembly. SNPs (top 5%) shows the top 5% associated SNPs within
the locus and are coloured by their correlation to the top SNP. Genes shows the
gene models from GENCODE version 19. Conservation was defined at each base
through the phyloP algorithmwhich assigns scores as2log10 P values under a null
hypothesis of neutral evolution calculated frompre-computed genomic alignment
of 100 vertebrate species49. Conserved sites are assignedpositive scores,while faster-
than-neutral evolving sites are given negative scores. TFBS conserved shows com-
putationally predicted transcription factor binding sites using the TransfacMatrix
Database (v.7.0) found inhuman,mouse and rat. Brainhistone (1.3 year) andbrain
histone (68 year) showmapsofhistone trimethylationathistoneH3Lys4 (H3K4me3),
an epigenetic mark for transcriptional activation, measured by ChIP-seq. These
measurements were made in neuronal nuclei (NeuN1) collected from prefrontal
cortex of post-mortemhumanbrain50.CpGmethylationwasgeneratedusingmeth-
ylatedDNAimmunoprecipitationand sequencing frompostmortemhuman frontal
cortex of a 57-year-old male51. DNaseI hypersens displays DNaseI hypersensitivity,
evidence of open chromatin, which was evaluated in postmortem human frontal
cerebrum from three donors (age 22–35), through the ENCODE consortium52.
Finally, hES Chrom State gives the predicted chromatin states based on computa-
tional integrationofChIP-seqdata fornine chromatinmarks inH1humanembry-
onic stem cell lines derived in the ENCODE consortium53.
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Extended Data Figure 1 | Outline of the genome-wide association
meta-analysis. StructuralT1-weighted brainMRI and biological specimens for
DNA extraction were acquired from each individual at each site. Imaging
protocols were distributed to and completed by each site for standardized
automated segmentation of brain structures and calculation of the ICV.
Volumetric phenotypeswere calculated from the segmentations. Genome-wide
genotyping was completed at each site using commercially available chips.
Standard imputation protocols to the 1000 Genomes reference panel (phase 1,
version 3) were also distributed and completed at each site. Each site completed
genome-wide association for each of the eight volumetric brain phenotypes
with the listed covariates. Statistical results fromGWAS files were uploaded to a
central site for quality checking and fixed effects meta-analysis.
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Extended Data Figure 2 | Ancestry inference via multi-dimensional scaling
plots. Multi-dimensional scaling (MDS) plots of the discovery cohorts to
HapMap III reference panels of known ancestry are displayed. Ancestry is
generally homogeneous within each group. In all discovery samples any
individuals with non-European ancestry were excluded before association. The
axes have been flipped to the same orientation for each sample for ease of
comparison. ASW, African ancestry in southwest USA; CEU, Utah residents
with northern and western European ancestry from the CEPH collection;
CHD, Chinese in metropolitan Denver, Colorado; GIH, Gujarati Indians in
Houston, Texas; LWK, Luhya in Webuye, Kenya; MEX, Mexican ancestry
in Los Angeles, California; MKK, Maasai in Kinyawa, Kenya; TSI, Tuscans in
Italy; YRI, Yoruba in Ibadan, Nigeria.
LETTER RESEARCH
G2015 Macmillan Publishers Limited. All rights reserved
Extended Data Figure 3 | Genomic function is annotated near novel
genome-wide significant loci. a–h, For each panel, zoomed-in Manhattan
plots (6400 kb from top SNP) are shownwith genemodels below (GENCODE
version 19). Plots below are zoomed to highlight the genomic region that
probably contains the causal variant(s) (r2. 0.8 from the top SNP). Genomic
annotations from the UCSC browser and ENCODE are displayed to indicate
potential functionality (see Methods for detailed track information). SNP
coverage is low in f owing to a common genetic inversion in the region. Each
plot was made using the LocusTrack software (http://gump.qimr.edu.au/
general/gabrieC/LocusTrack/).
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Extended Data Figure 4 | Quantile–quantile and forest plots from
meta-analysis of discovery cohorts. a, Quantile–quantile plots show that the
observed P values only deviate from the expected null distribution at the
most significant values, indicating that population stratification or cryptic
relatedness are not unduly inflating the results. This is quantified through
the genomic control parameter (l; which evaluates whether the median test
statistic deviates from expected)54. l values near 1 indicate that the median test
statistic is similar to those derived from a null distribution. Corresponding
meta-analysis Manhattan plots can be found in Fig. 1. b, Forest plots show
the effect at each of the contributing sites to the meta-analysis. The size of the
dot is proportional to the sample size, the effect is shown by the position on
the x axis, and the standard error is shown by the line. Sites with an asterisk
indicate the genotyping of a proxy SNP (in perfect linkage disequilibrium
calculated from 1000 Genomes) for replication.
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Extended Data Figure 5 | Influence of patients with neuropsychiatric
disease, age and gender on association results. a, Scatterplot of effect sizes
including and excluding patientswith neuropsychiatric disorders for nominally
significant SNPs. For each of the eight volumetric phenotypes, SNPs with
P, 13 1025 in the full discovery set meta-analysis were also evaluated
excluding the patients. The beta values from regression, ameasure of effect size,
are plotted (blue dots) along with a line of equivalence between the two
conditions (red line). The correlation between effect sizes with and without
patients was very high (r. 0.99), showing that the SNPswith significant effects
on brain structure are unlikely to be driven by the diseased individuals.
b, Meta-regression comparison of effect size with mean age at each site. Each
site has a corresponding number and coloured dot in each graph. The size of
each dot is based on the standard error such that bigger sites with more
definitive estimates have larger dots (and more influence on the meta-
regression). The age range of participants covered most of the lifespan
(9–97 years), but only one of these eight loci showed a significant relationship
with the mean age of each cohort (rs608771 affecting putamen volume).
c, Meta-regression comparison of effect size with the proportion of females
at each site. No loci showed evidence of moderation by the proportion of
females in a given sample. However, the proportion of females at each site has a
very restricted range, so results should be interpreted with caution. Plotted
information follows the same convention as described in b. The sites are
numbered in the following order: (1) AddNeuroMed, (2) ADNI,
(3) ADNI2GO, (4) BETULA, (5) BFS, (6) BIG, (7) BIG-Rep, (8) BrainSCALE,
(9) BRCDECC, (10) CHARGE, (11) EPIGEN, (12) GIG, (13) GSP,
(14) HUBIN, (15) IMAGEN, (16) IMpACT, (17) LBC1936, (18) Lieber,
(19) MAS, (20) MCIC, (21) MooDS, (22) MPIP, (23) NCNG, (24) NESDA,
(25) neuroIMAGE, (26) neuroIMAGE-Rep, (27) NIMH, (28) NTR-Adults,
(29) OATS, (30) PAFIP, (31) QTIM, (32) SHIP, (33) SHIP-TREND, (34) SYS,
(35) TCD-NUIG, (36) TOP, (37) UCLA-BP-NL and (38) UMCU.
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Extended Data Figure 6 | Cross-structure analyses. a, Radial plots of effect
sizes from the discovery sample for all genome-wide significant SNPs identified
in this study. Plots indicate the effect of each genetic variant, quantified as
percentage variance explained, on the eight volumetric phenotypes studied. As
expected, the SNPs identified with influence on a phenotype show the highest
effect size for that phenotype: putamen volume (rs945270, rs62097986,
rs608771 and rs683250), hippocampal volume (rs77956314 and rs61921502),
caudate volume (rs1318862) and ICV (rs17689882). In general much smaller
effects are observed on other structures. b, Correlation heat map of GWAS
test statistics (t-values) and hierarchical clustering55. Independent SNPs were
chosen within an linkage disequilibrium block based on the highest association
in the multivariate cross-structure analysis described in Extended Data Fig. 6c.
Two heat maps are shown taking only independent SNPs with either
P, 13 1024 (left) or P, 0.01 (right) in the multivariate cross-structure
analysis. Different structures are labelled in developmentally similar regions by
the colour bar on the top and side of the heat map including basal ganglia
(putamen, pallidum, caudate and accumbens; blue), amygdalo–hippocampal
complex (hippocampus and amygdala; red), thalamus (turquoise) and ICV
(black). Hierarchical clustering showed that developmentally similar regions
have mostly similar genetic influences across the entire genome. The low
correlation with the ICV is owing to it being used as a covariate in the
subcortical structure GWAS associations. c, A multivariate cross-structure
analysis of all volumetric brain traits. A Manhattan plot (left) and
corresponding quantile–quantile plot (right) of multivariate GWAS analysis of
all traits (volumes of the accumbens, amygdala, caudate, hippocampus,
pallidum, putamen, thalamus, and ICV) in the discovery data set using the
TATES method9 is shown. Multivariate cross-structure analysis confirmed the
univariate analyses (see Table 1), but did not reveal any additional loci
achieving cross-structure levels of significance.
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Extended Data Figure 7 | Pathway analysis of GWAS results for each brain
structure. A pathway analysis was performed on each brain volume GWAS
using KGG42 to conduct gene-based tests and the Reactome database for
pathway definition43. Pathway-wide significance was calculated using a
Bonferroni correction threshold accounting for the number of pathways and
traits tested such that Pthresh 5 0.05/(671 pathways3 7 independent
traits)5 1.063 1025 and is shown here as a red line. The number of
independent traits was calculated by accounting for the non-independence of
each of the eight traits examined (described in the Methods). Variants that
influence the putamen were clustered near genes known to be involved in
DSCAM interactions, neuronal arborization and axon guidance56. Variants
that influence intracranial volume are clustered near genes involved in EGFR
and phosphatidylinositol-3-OH kinase (PI(3)K)/AKT signalling pathways,
known to be involved in neuronal survival57. All of these represent potential
mechanisms bywhich genetic variants influence brain structure. It is important
to note that the hybrid set-based test (HYST) method for pathway analysis
used here can be strongly influenced by a few highly significant genes, as was
the case for putamen hits in which DCC and BCL2L1 were driving the
pathway results.
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Extended Data Figure 8 | Spatio-temporal maps showing expression of
genes near the four significant putamen loci over time and throughout
regions of the brain. Spatio-temporal gene expression13 was plotted as
normalized log2 expression. Different areas of the neocortex (A1C, primary
auditory cortex; DFC, dorsolateral prefrontal cortex; IPC, posterior inferior
parietal cortex; ITC, inferior temporal cortex; MFC, medial prefrontal cortex;
M1C, primary motor cortex; OFC, orbital prefrontal cortex; STC, superior
temporal cortex; S1C, primary somatosensory cortex; VFC, ventrolateral
prefrontal cortex; V1C, primary visual cortex) as well as subcortical areas
(AMY, amygdala; CBC, cerebellar cortex; HIP, hippocampus; MD,
mediodorsal nucleus of the thalamus; STR, striatum) are plotted from 10
post-conception weeks (PCW) to more than 60 years old. Genes that probably
influence putamen volume are expressed in the striatum at some point during
the lifespan. After late fetal development, KTN1 is expressed in the human
thalamus, striatum and hippocampus and is more highly expressed in the
striatum than the cortex. Most genes seem to have strong gradients of
expression across time, with DCCmost highly expressed during early prenatal
life, and DLG2 most highly expressed at mid-fetal periods and throughout
adulthood. BCL2L1, which inhibits programmed cell death, has decreased
striatal expression at the end of neurogenesis (24–38 PCW), a periodmarked by
increased apoptosis in the putamen15.
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ExtendedData Figure 9 | CTCF-binding sites in the vicinity of the putamen
locusmarked by rs945270. CTCF-binding sites from theENCODEproject are
displayed from the database CTCFBSDB 2.0 (ref. 23) from two different cell
types: embryonic stem cells (track ENCODE_Broad_H1-hESC_99540) and a
neuroblastoma cell line differentiated with retinoic acid (ENCODE_UW_SK-
N-SH_RA_97826). A proxy SNP to the top hit within the locus, rs8017172
(r25 1.0 to rs945270), lies within a CTCF-binding site called based on
ChIP-seq data in the embryonic stem cells and near the binding site in neural
SK-N-SH cells. As this is the lone chromatin mark in the intergenic region
(see Extended Data Fig. 3), it suggests that the variant may disrupt a
CTCF-binding site and thereby influence transcription of surrounding genes.
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Extended Data Figure 10 | Shape analysis in 1,541 young healthy subjects
shows consistent deformations of the putamen regardless of segmentation
protocol. a, b, The distance from a medial core to surfaces derived from
FSL FIRST (a; identical to Fig. 2c) or FreeSurfer (b) segmentations was derived
in the same 1,541 subjects. Each copy of the rs945270-C allele was significantly
associated with an increased width in coloured areas (false discovery rate
corrected at q5 0.05) and the degree of deformation is labelled by colour.
The orientation is indicated by arrows. A, anterior; I, inferior; P, posterior;
S, superior. Shape analysis in both software suites gives statistically significant
associations in the same direction. Although the effects aremore widespread in
the FSL segmentations, FreeSurfer segmentations also show overlapping
regions of effect, which appears strongest in anterior and superior sections.
LETTER RESEARCH
G2015 Macmillan Publishers Limited. All rights reserved
Extended Data Figure 11 | The phenotypic variance explained by all
common variants in this study. a, Twin-based heritability (with 95%
confidence intervals), measuring additive genetic influences from both
common and rare variation, is shown for comparison with common variant
based heritability (see Methods). b, The median estimated percentage of
phenotypic variance explained by all SNPs (and 95% confidence interval) is
given for each brain structure studied41. The full genome-wide association
results from common variants explain approximately 7–15% of variance
depending on the phenotype. c, The median estimated variance explained by
each chromosome is shown for each phenotype. d, Some chromosomes explain
more variance than would be expected by their length, for example
chromosome 18 in the case of the putamen, which contains the DCC gene.
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